New drug therapies could be developed to prevent hereditary diseases, research reveals. 

According to a study published in the latest issue of Science, researchers have pinpointed a cellular mechanism involved in the inheritance of genetic mutations. It is believed the findings could help develop treatments to reduce the risk of babies being born with serious, incurable mitochondrial diseases. 

The study suggests the transmission of genetic alterations involves a process that blocks the elimination of mutant mitochondria while increasing their number in cells. This explains how these variants ‘escape’ selection and can cause diseases in the future. The research shows that, by developing new drug therapies, mitochondrial diseases could be prevented. 

“Mitochondrial diseases can cause devastating disabilities and even prevent some families from having children,” Patrick Chinnery, Professor of Neurology at the University of Cambridge and the corresponding author of the study, told Agência FAPESP. “The United Kingdom has approved a new form of in vitro fertilisation that can prevent their transmission, but other than that, we have no way of preventing these diseases, and there are few treatments available.” 

“Our discovery points to a possible new drug therapy that could help stop these diseases in the future, allowing families to have healthy children.” 

Explaining mitochondrial function

Mitochondria are the main source of energy in all cells and have their own DNA. Shortly after fertilisation, the embryo has a ‘quality control’ system that eliminates ‘defective’ mitochondria, a process called mitophagy. During this process, the protein ubiquitin acts as a marker that directs altered molecules to destruction. 

Mitophagy maintains harmony between mitochondrial DNA (mtDNA) and nuclear DNA, ensuring compatibility between the two. However, because mtDNA mutates at a rate approximately 15 times higher than the nuclear genome, this poses a challenge to their symbiotic relationship. 

The enzyme USP30 (short for ubiquitin-specific protease 30) acts on ubiquitin by blocking it and preventing ‘labelling,’ which reduces elimination. Imbalances in USP30 have been linked to several diseases, including mitochondrial and neurodegenerative diseases. A large accumulation of mutations results in incompatibility, causing mitochondrial dysfunction and negative health effects. 

Mitochondrial diseases are inherited metabolic disorders that affect mitochondrial function, potentially resulting in damage to vital organs such as the brain and heart. The most common include Leber’s hereditary optic neuropathy (LHON), Leigh syndrome, and MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes). 

Depending on which cells are affected, symptoms can range from growth problems and cognitive developmental delays to muscle weakness, pain, vision and/or hearing loss, and seizures. 

Treating mitochondrial diseases

In the study, scientists proposed two possibilities for treating mitochondrial diseases. This included treating early embryos after in vitro fertilisation, reducing the number of cells with a high mutational load before implantation, or targeting USP30 therapeutically to treat or prevent rare hereditary diseases. 

Researchers have now demonstrated in vivo that cells respond to mtDNA mutations by deactivating the marker effect of ubiquitin instead of activating new biosynthetic pathways. 

Using mice, the scientists discovered that mutations are not perceived in the first days after fertiliszation because USP30 is overactivated, which inhibits ubiquitin from marking defective mitochondrial DNA and blocking its elimination. This results in an increase in mitochondrial mass and genome, which allows the transmission of mutations that can cause diseases. 

In the study, the group demonstrated that preventing USP30 from acting with the inhibitor Compound 39 (CMPD39) creates a ‘window of elimination’ for altered mitochondrial DNA shortly after fertilisation. During this period, the embryo naturally eliminates paternal mitochondria. Unlike nuclear DNA, where children inherit half from each parent, mtDNA is transmitted solely from the mother. 

A team of researchers at Newcastle University recently performed a successful innovative in vitro fertilisation technique involving the replacement of mothers’ mutant mitochondrial DNA with mitochondria from healthy donors. The treatment, called ‘mitochondrial replacement therapy’, led to eight babies being born, who may be protected from mitochondrial diseases as a result. 

“We know that this technique involving mitochondrial replacement is controversial and has only been approved, for now, in England and Australia,” said Marcos Roberto Chiaratti, Professor at the Department of Genetics and Evolution at the Federal University of São Carlos (UFSCar). “With our research, we show that there are other possibilities, mainly pharmacological, to treat the embryo and prevent the transmission of these types of disease.” 

 

Bruno Quinney, Content Team, DDW